13F HOLDINGS REPORT
Athyrium Capital Management, LP
Quarter ended Q3 2023 · Filed August 14, 2023 · Accession 0001123292-23-000094
Total Value
$154.1M
Positions
7
Other Managers
0
Confidential Omitted
No
Holdings (7)
| # | Issuer | Ticker / CUSIP | Shares | Value | % of Filing |
|---|---|---|---|---|---|
| 1 | Biora Inc. | 74319FAB3 | 103,500,000 | $60.5M | 39.23% |
| 2 | Omeros Corp | OMER | 71,979,000 | $52.8M | 34.22% |
| 3 | Omeros Corp | OMER | 11,005,000 | $11.0M | 7.16% |
| 4 | Paratek Pharmaceuticals Inc. | 699374AB0 | 9,000,000 | $8.8M | 5.74% |
| 5 | RVL PHARMACEUTICALS PLC | G6S41R101 | 14,600,444 | $8.2M | 5.31% |
| 6 | Biora Inc. | 74319F305 | 1,694,481 | $6.5M | 4.23% |
| 7 | PUMA BIOTECHNOLOGY INC | PBYI | 1,792,114 | $6.3M | 4.10% |